Quantcast
Mummy Remains Refute Antiquity Of Ankylosing Spondylitis

Mummy Remains Refute Antiquity Of Ankylosing Spondylitis

Provided by Dawn Peters, Wiley No signs of disabling spinal arthritis in Egyptian mummies Ankylosing spondylitis is a systemic disease that causes inflammation in the spinal joints and was thought to have affected members of the ancient...

Latest autoimmune diseases Stories

2014-10-22 12:30:14

Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA, Oct. 22, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on Cimzia(®) (certolizumab pegol) at the American College of Gastroenterology's (ACG) 2014 Annual Scientific Meeting in Philadelphia,...

2014-10-22 04:22:24

Immune Pharmaceuticals Recently Initiated Phase II Clinical Trial in Ulcerative Colitis CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Oct. 22, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces that Dr. Tomer Adar, a gastro-enterologist at the Institute for Digestive Diseases at Shaare Zedek Medical Center, Israel, is presenting today at the United European Gastro-Enterology week in Vienna, Austria an abstract entitled "The...

2014-10-20 08:30:43

TARRYTOWN, N.Y. and PARIS, Oct. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical...

2014-10-19 16:21:24

Largest retrospective study of its kind reveals that nearly 60 percent of patients with both uveitis and MS are diagnosed with each within a 5-year span CHICAGO, Oct. 19, 2014 /PRNewswire-USNewswire/ -- The results of the largest retrospective study of multiple sclerosis (MS) in uveitis patients has revealed that nearly 60 percent of patients with both diseases were diagnosed with each within a five-year span. The study is being presented today at AAO 2014, the 118(th) annual...

2014-10-15 12:27:27

A Substantial Need Remains for Emerging SLE Biologics That Can Prevent Acute Flares and That Treat Severe Manifestations, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that although use of biologics in SLE has increased in the past three years, largely due to uptake of GlaxoSmithKline's Benlysta, overall physician-reported patient share of biologics remains modest. Less than half of SLE patients considered...

2014-10-15 08:31:21

AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With No Systemic Exposure GHENT, Belgium, Oct. 15, 2014 /PRNewswire/ -- ActoGeniX, a clinical stage biopharmaceutical company, today announced positive results of a Phase 1 study in healthy volunteers of AG014, an oral administration of the anti-TNF-alpha antibody certolizumab for Inflammatory Bowel Disease (IBD). The Phase 1 study results show that the product is safe and well tolerated while providing...

2014-10-13 12:27:24

U.S. and international grantees will receive funds to support innovative, collaborative approaches to investigate potential new treatments and therapies for Inflammatory Bowel Disease. OAKLAND, Calif., Oct. 13, 2014 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation announced today that it will grant $2.2 million to scientists to conduct Inflammatory Bowel Disease (IBD) research. The Rainin Foundation offers support for cutting-edge projects that typically are not eligible for funding...

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-10-13 08:27:34

Be Joint Smart to educate roughly 28,000 local residents with PsA about their disease PORTLAND, Ore., Oct. 13, 2014 /PRNewswire-USNewswire/ -- If you're one of the roughly 28,000 Seattle metro residents struggling with pain from psoriatic arthritis (PsA)--an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons--learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at...

2014-10-09 00:20:40

Empire State Building Glows Purple to Celebrate Lupus Foundation of America's National Gala and to Call Attention to Need for Increased Awareness and Investment in Lupus Research NEW YORK, Oct. 8, 2014 /PRNewswire-USNewswire/ -- On Wednesday, October 8, patients, caregivers, researchers, celebrities and supporters gathered at Gotham Hall in New York City for the Lupus Foundation of America's Evening of Hope National Gala. The event raised critical funds needed to support the...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.